Senhwa Biosciences, Inc. has entered into a share purchase agreement with GEM Global Yield LLC SCS and GEM Yield Bahamas Limited involving a commitment of up to NT$500 million.

• Agreement Terms: GEM has committed up to NT$500 million under the agreement, with share purchases to occur over the next three to five years, subject to the agreement’s terms.
• Operational Purpose: The funding is expected to support the clinical development of Senhwa’s oncology pipeline, potential in-licensing opportunities, and AI-enabled pipeline expansion.

This summary is based on a press release issued by Senhwa Biosciences, Inc. via PR Newswire.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.